IL138160A0 - Quinoline derivatives - Google Patents
Quinoline derivativesInfo
- Publication number
- IL138160A0 IL138160A0 IL13816099A IL13816099A IL138160A0 IL 138160 A0 IL138160 A0 IL 138160A0 IL 13816099 A IL13816099 A IL 13816099A IL 13816099 A IL13816099 A IL 13816099A IL 138160 A0 IL138160 A0 IL 138160A0
- Authority
- IL
- Israel
- Prior art keywords
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9801474A SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Quinoline Derivatives |
| PCT/SE1999/000676 WO1999055678A1 (en) | 1998-04-27 | 1999-04-26 | Quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL138160A0 true IL138160A0 (en) | 2001-10-31 |
Family
ID=20411103
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13816099A IL138160A0 (en) | 1998-04-27 | 1999-04-26 | Quinoline derivatives |
| IL138160A IL138160A (en) | 1998-04-27 | 2000-08-30 | Quinoline derivatives |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL138160A IL138160A (en) | 1998-04-27 | 2000-08-30 | Quinoline derivatives |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1073639B1 (id) |
| JP (1) | JP4045069B2 (id) |
| KR (1) | KR100571534B1 (id) |
| CN (1) | CN1113057C (id) |
| AP (1) | AP1293A (id) |
| AT (1) | ATE228505T1 (id) |
| AU (1) | AU747550B2 (id) |
| BR (1) | BR9909925B1 (id) |
| CA (1) | CA2329788C (id) |
| CZ (1) | CZ297439B6 (id) |
| DE (1) | DE69904162T2 (id) |
| DK (1) | DK1073639T3 (id) |
| EE (1) | EE04275B1 (id) |
| ES (1) | ES2188242T3 (id) |
| HK (1) | HK1036618A1 (id) |
| HR (1) | HRP20000726B1 (id) |
| HU (1) | HU227709B1 (id) |
| ID (1) | ID26277A (id) |
| IL (2) | IL138160A0 (id) |
| IS (1) | IS2082B (id) |
| ME (1) | ME00870B (id) |
| NO (1) | NO315606B1 (id) |
| NZ (1) | NZ506641A (id) |
| OA (1) | OA11547A (id) |
| PL (1) | PL190441B1 (id) |
| PT (1) | PT1073639E (id) |
| RS (1) | RS50029B (id) |
| RU (1) | RU2197481C2 (id) |
| SE (1) | SE9801474D0 (id) |
| TR (1) | TR200003061T2 (id) |
| UA (1) | UA60354C2 (id) |
| WO (1) | WO1999055678A1 (id) |
| ZA (1) | ZA200004601B (id) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002320D0 (sv) * | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| KR100908655B1 (ko) | 2002-11-27 | 2009-07-21 | 엘지디스플레이 주식회사 | 데이터 공급시간의 변조방법과 이를 이용한액정표시장치의 구동방법 및 장치 |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
| US7838522B2 (en) | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| BRPI0516383A (pt) | 2004-12-21 | 2008-09-02 | Serono Lab | derivados cìclicos de sulfonil amino e o uso dos mesmos |
| WO2006079653A1 (en) | 2005-01-31 | 2006-08-03 | Laboratoires Serono S.A. | N-hydroxyamide derivatives and use thereof |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| EA013816B1 (ru) | 2005-09-01 | 2010-08-30 | Арес Трейдинг С.А. | Лечение неврита зрительного нерва |
| BRPI0617477A2 (pt) * | 2005-10-19 | 2011-07-26 | Teva Pharma | mistura de partÍculas cristalinas de laquinimod sàdica, composiÇço, processo de cristalizaÇço de laquinimod sàdica, laquinimod sàdica, e, processo para produzir uma composiÇço farmacÊutica |
| EP2035001B1 (en) | 2006-06-12 | 2011-11-09 | Teva Pharmaceutical Industries Limited | Stable laquinimod preparations |
| PL2682120T3 (pl) | 2007-12-20 | 2017-02-28 | Teva Pharmaceutical Industries, Ltd. | Stabilne preparaty lakwinimodu |
| BRPI0913518A2 (pt) * | 2008-09-03 | 2016-07-26 | Teva Pharma | composto, composição farmacêutica, e, método de tratamento de um distúrbio mediado por função imune |
| ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
| EP3064206B1 (en) | 2009-08-10 | 2019-03-20 | Active Biotech AB | Treatment of huntington's disease using laquinimod |
| JP5819328B2 (ja) * | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
| BR112012021905A2 (pt) | 2010-03-03 | 2015-09-29 | Teva Pharma | tratamento de nefrite lúpica usando laquinimod |
| PT2542080T (pt) * | 2010-03-03 | 2016-11-16 | Teva Pharma | Tratamento de artrite causada por lúpus usando laquinimod |
| WO2011116091A1 (en) | 2010-03-17 | 2011-09-22 | Novartis Ag | Dispenser |
| CA2802006C (en) | 2010-07-09 | 2018-09-25 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| SG10201505236YA (en) * | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| AU2011274502A1 (en) * | 2010-07-09 | 2013-02-28 | Teva Pharmaceutical Industries Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| EP2444086A1 (en) | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Combinations comprising DHODH inhibitors and COX inhibitors |
| US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| BR112015010193A2 (pt) | 2012-11-07 | 2017-07-11 | Teva Pharma | sais de amina de laquinimod |
| RU2545056C2 (ru) * | 2012-12-10 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здавоохранения и социального развития Российской Федерации (ГБОУ ВПО ПГФА Минздравсоцразвития России) | Противовоспалительное и анальгетическое средство на основе изопропиламида 1,2-дигидро-1н-2-оксоцинхониновой кислоты |
| PE20151526A1 (es) * | 2013-02-15 | 2015-11-20 | Teva Pharma | Tratamiento de formas progresivas de esclerosis multiple con laquinimod |
| KR20150143499A (ko) | 2013-03-14 | 2015-12-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법 |
| MX2016013944A (es) | 2014-04-29 | 2017-01-09 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad. |
| AU2015316824B2 (en) | 2014-09-23 | 2020-10-29 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of multiple myeloma |
| KR102525805B1 (ko) | 2014-11-19 | 2023-04-25 | 액티브 바이오테크 에이비 | 백혈병 치료용 퀴놀린 카르복사미드 |
| ES2921360T3 (es) | 2019-12-19 | 2022-08-24 | Active Biotech Ab | Compuestos para el tratamiento de enfermedades oculares asociadas a una vascularización excesiva |
| EP4114368A1 (en) | 2020-03-03 | 2023-01-11 | Active Biotech AB | Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy |
| CN116782902A (zh) | 2020-07-23 | 2023-09-19 | 伊拉兹马斯大学鹿特丹医学中心 | 作为骨髓增殖性肿瘤中的新治疗靶标的s100蛋白 |
| US20240091215A1 (en) | 2021-01-18 | 2024-03-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
| IL308542A (en) | 2021-05-25 | 2024-01-01 | Active Biotech Ab | Multiparticles of tesquinimod and their use |
| WO2023275248A1 (en) | 2021-07-02 | 2023-01-05 | Active Biotech Ab | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
-
1998
- 1998-04-27 SE SE9801474A patent/SE9801474D0/xx unknown
-
1999
- 1999-04-26 PT PT99947036T patent/PT1073639E/pt unknown
- 1999-04-26 AT AT99947036T patent/ATE228505T1/de active
- 1999-04-26 RS YUP-612/00A patent/RS50029B/sr unknown
- 1999-04-26 EP EP99947036A patent/EP1073639B1/en not_active Expired - Lifetime
- 1999-04-26 DK DK99947036T patent/DK1073639T3/da active
- 1999-04-26 OA OA1200000301A patent/OA11547A/en unknown
- 1999-04-26 IL IL13816099A patent/IL138160A0/xx active IP Right Grant
- 1999-04-26 AU AU43013/99A patent/AU747550B2/en not_active Ceased
- 1999-04-26 ID IDW20002183A patent/ID26277A/id unknown
- 1999-04-26 UA UA2000085078A patent/UA60354C2/uk unknown
- 1999-04-26 NZ NZ506641A patent/NZ506641A/en not_active IP Right Cessation
- 1999-04-26 RU RU2000129672/04A patent/RU2197481C2/ru not_active IP Right Cessation
- 1999-04-26 ES ES99947036T patent/ES2188242T3/es not_active Expired - Lifetime
- 1999-04-26 JP JP2000545838A patent/JP4045069B2/ja not_active Expired - Lifetime
- 1999-04-26 EE EEP200000613A patent/EE04275B1/xx unknown
- 1999-04-26 AP APAP/P/2000/001933A patent/AP1293A/en active
- 1999-04-26 KR KR1020007011944A patent/KR100571534B1/ko not_active IP Right Cessation
- 1999-04-26 CZ CZ20003849A patent/CZ297439B6/cs not_active IP Right Cessation
- 1999-04-26 TR TR2000/03061T patent/TR200003061T2/xx unknown
- 1999-04-26 WO PCT/SE1999/000676 patent/WO1999055678A1/en active IP Right Grant
- 1999-04-26 DE DE69904162T patent/DE69904162T2/de not_active Expired - Lifetime
- 1999-04-26 ME MEP-2000-612A patent/ME00870B/me unknown
- 1999-04-26 CN CN99805581A patent/CN1113057C/zh not_active Expired - Fee Related
- 1999-04-26 BR BRPI9909925-0A patent/BR9909925B1/pt not_active IP Right Cessation
- 1999-04-26 PL PL99343420A patent/PL190441B1/pl unknown
- 1999-04-26 CA CA002329788A patent/CA2329788C/en not_active Expired - Fee Related
- 1999-04-26 HU HU0102084A patent/HU227709B1/hu not_active IP Right Cessation
-
2000
- 2000-08-30 IL IL138160A patent/IL138160A/en not_active IP Right Cessation
- 2000-08-31 IS IS5615A patent/IS2082B/is unknown
- 2000-09-01 ZA ZA200004601A patent/ZA200004601B/en unknown
- 2000-10-19 NO NO20005254A patent/NO315606B1/no not_active IP Right Cessation
- 2000-10-26 HR HR20000726A patent/HRP20000726B1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 HK HK01105489A patent/HK1036618A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL143782A0 (en) | Quinoline derivatives | |
| PL343420A1 (en) | Quinoline derivatives | |
| PL345388A1 (en) | Quinoline derivatives | |
| GB9904103D0 (en) | Quinoline derivatives | |
| IL143859A0 (en) | 1,2-annelated quinoline derivatives | |
| IL140009A0 (en) | Quinoline derivatives | |
| IL141226A0 (en) | 1h-imidazopyridine derivatives | |
| PL345540A1 (en) | Thiobenzimidazole derivatives | |
| HRP990011B1 (en) | Benzosulfone derivatives | |
| GB9910384D0 (en) | Alpha-ketoamide derivatives | |
| EG23802A (en) | 2-Phenylpyran-4-one derivatives | |
| GB9827729D0 (en) | Thieno-indole derivatives | |
| EG24161A (en) | Carbostyril derivatives | |
| EP1061912A4 (en) | PHENANTHROFURANDERIVATE | |
| IL139276A0 (en) | Cyclohexenondioxthio chromanoyl derivatives | |
| HK1042478A1 (zh) | 2-氧代-2h-喹啉衍生物 | |
| GB9904104D0 (en) | Quinoline derivatives | |
| GB9904105D0 (en) | Quinoline derivatives | |
| GB9904102D0 (en) | Quinoline derivatives | |
| GB9816279D0 (en) | Arylthiazolidinedione derivatives | |
| SI1051395T1 (sl) | N-hidroksiformamidni derivati |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |